{"id":8136,"date":"2023-10-12T08:53:00","date_gmt":"2023-10-12T08:53:00","guid":{"rendered":"https:\/\/www.acarix.com\/invitation-to-digital-live-presentation-with-acarix-2\/"},"modified":"2024-11-18T19:04:47","modified_gmt":"2024-11-18T19:04:47","slug":"invitation-to-digital-live-presentation-with-acarix-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/invitation-to-digital-live-presentation-with-acarix-2\/","title":{"rendered":"Invitation to digital live presentation with Acarix"},"content":{"rendered":"
\n

Acarix, a leader in acoustic and AI-based cardiac diagnostics, invites to a digital investor presentation on Friday October 13, 2023 at 2.00 pm (CEST) with the Company’s acting CEO Fred Colen by reason of the ongoing rights issue. An overview of what Acarix is focused on and how the proceeds of the rights issue will be used will be presented.<\/strong><\/p>\n<\/div>\n

\n

Erik Penser Bank will also provide a summary of the rights issue and how to subscribe for shares.<\/p>\n

The webcast will be available at https:\/\/youtube.com\/live\/kqyOQL46OJw?feature=share<\/a><\/p>\n

The presentation will be available after the webcast at https:\/\/www.acarix.com\/for-investors\/investor-presentations<\/a><\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Fred Colen, acting CEO, email fred.colen@acarix.com<\/a> 
Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, certifiedadviser@penser.se<\/a>) is Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a>. <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Invitation to digital live presentation with Acarix<\/a><\/p>\n<\/div>\n